Scarica l'app Stockscreener
45.77
3.95%
-1.88
Precedente Chiudi:
$47.65
Aprire:
$47.63
Volume 24 ore:
279.87K
Relative Volume:
0.81
Capitalizzazione di mercato:
$2.20B
Reddito:
-
Utile/perdita netta:
$-107.28M
Rapporto P/E:
-17.58
EPS:
-2.6031
Flusso di cassa netto:
$-80.71M
1 W Prestazione:
-6.15%
1M Prestazione:
+8.46%
6M Prestazione:
+56.00%
1 anno Prestazione:
+198.18%
Intervallo 1D:
$45.52
$48.00
Intervallo di 1 settimana:
$45.52
$50.34
Portata 52W:
$14.21
$52.93
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
45.77 | 2.30B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Strong Buy |
| 2026-02-02 | Iniziato | Wells Fargo | Overweight |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-09-16 | Iniziato | Truist | Buy |
| 2025-08-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Mostra tutto
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Rapport Therapeutics' RAP-219 shows promise wit... - Pluang
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise - Seeking Alpha
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 404 Shares - MarketBeat
Does Widening Losses And Higher EPS Drag Change The Bull Case For Rapport Therapeutics (RAPP)? - simplywall.st
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month HighShould You Buy? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Given "Buy" Rating at BTIG Research - MarketBeat
Trv Gp Vi LLC Takes Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Trv Gp V LLC Takes $261.71 Billion Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Capital International Investors Reduces Stake in Rapport Therapeutics Inc (RAPP) - GuruFocus
Raymond James Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Raymond James raises Rapport Therapeutics price target on bipolar catalyst potential - Investing.com Canada
Johnson & Johnson Purchases New Stake in Rapport Therapeutics, Inc. $RAPP - MarketBeat
How Rapport Therapeutics Inc. (RAPP) Affects Rotational Strategy Timing - Stock Traders Daily
Walleye Capital LLC Purchases Shares of 102,163 Rapport Therapeutics, Inc. $RAPP - MarketBeat
Brokers Offer Predictions for RAPP Q1 Earnings - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 28,958 Shares - MarketBeat
Abraham Ceesay Sells 22,541 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan - Stock Titan
Rapport Therapeutics (NASDAQ:RAPP) Given New $66.00 Price Target at HC Wainwright - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year HighTime to Buy? - MarketBeat
Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million - Bitget
Rapport Therapeutics, Inc. $RAPP Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Do Widening Losses At Rapport Therapeutics (RAPP) Reveal Strategic Investment Or Emerging Financial Strain? - webull.com
Q3 Earnings Estimate for RAPP Issued By HC Wainwright - MarketBeat
Rapport Therapeutics Inc (RAPP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rapport Therapeutics (NASDAQ:RAPP) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Rapport Therapeutics Inc (RAPP) Stock News Today - TradingKey
Analysts Offer Insights on NA Companies: Starz Entertainment Corp (STRZ), Bluelinx Holdings (BXC) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and Honeywell Aerospace (HONA) - The Globe and Mail
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Rapport Therapeutics stock hits all-time high at 44.38 USD By Investing.com - Investing.com India
Rapport Therapeutics stock hits all-time high at 44.38 USD - Investing.com
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 52-Week HighHere's What Happened - MarketBeat
Rapport Therapeutics: Advancing Phase 3 Epilepsy Pipeline and De-Risked Development Path Underpins Buy Rating - TipRanks
Rapport Therapeutics (NASDAQ:RAPP) Announces Earnings Results - MarketBeat
Rapport Therapeutics' (RAPP) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Rapport Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Rapport Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(RAPP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Rapport Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.19) — 10-Q Summary - TradingView
Rapport Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rapport Therapeutics (Nasdaq: RAPP) books $20,000 from RAP-219 China deal - Stock Titan
Rapport Therapeutics reports Q2 2026 net loss $56.6M, cash $436.1M, advances RAP-219 to Phase 3 - TradingView
Rapport Therapeutics Reports $56.6 Million Q2 Net Loss - Quiver Quantitative
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update - The Manila Times
RAPP Q2'26 Earnings: EPS estimate is (0.96) USD - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Report: Analyst Consensus Suggests a 36.95% Upside Potential - DirectorsTalk Interviews
Rapport Therapeutics Inc. (RAPP) Surges 2.34%: Biotech Momentum Building Above Key SupportSell Signal Alerts - dars.gov.et
William Blair Initiates Rapport Therapeutics at Outperform - marketscreener.com
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rapport Therapeutics Inc Azioni (RAPP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Yeleswaram Krishnaswamy | Chief Development Officer |
Aug 25 '26 |
Sale |
50.64 |
37,000 |
1,873,605 |
195,862 |
| Yeleswaram Krishnaswamy | Chief Development Officer |
Aug 24 '26 |
Sale |
50.00 |
13,160 |
657,978 |
232,862 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):